Accepted for Publication: September 20, 2019.
Corresponding Author: Alexandra Lansky, MD, Division of Cardiovascular Medicine, Yale School of Medicine, 135 College St, Ste 101, New Haven, CT 06510 (alexandra.lansky@yale.edu).
Published Online: November 13, 2019. doi:10.1001/jamacardio.2019.4367
Author Contributions: Drs Saito and Lansky had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Saito, Nazif, Baumbach, Tchétché, Latib, Forrest, Prendergast, Lansky.
Acquisition, analysis, or interpretation of data: Saito, Tchétché, Kaple, Forrest.
Drafting of the manuscript: Saito, Latib, Forrest.
Critical revision of the manuscript for important intellectual content: Nazif, Baumbach, Tchétché, Latib, Kaple, Forrest, Prendergast, Lansky.
Administrative, technical, or material support: Latib, Forrest.
Supervision: Latib, Forrest.
Conflict of Interest Disclosures: Dr Nazif reports grants, personal fees, and nonfinancial support from Edwards Lifesciences, Medtronic, and Boston Scientific outside the submitted work. Dr Latib is on the advisory boards of Medtronic and Abbott and reported personal fees from Medtronic, Abbott, and Edwards Lifesciences outside the submitted work. Dr Forrest reports personal fees and grants from Edwards Lifesciences and Medtronic outside the submitted work. Dr Lansky reports grants from Abbott Vascular and personal fees from Venous Medical/Keystone Heart, KSH, Microport, Sinomed, and AstraZeneca outside the submitted work. Dr Saito reported grants from SENSHIN Medical Research Foundation outside the submitted work. Dr Baumbach reported grants and personal fees from Abbott and personal fees from AstraZeneca, Microport, and Sinomed outside the submitted work. No other disclosures were reported.
2.Nishimura
RA, Otto
CM, Bonow
RO,
et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
J Am Coll Cardiol. 2017;70(2):252-289. doi:
10.1016/j.jacc.2017.03.011PubMedGoogle ScholarCrossref 5.Leon
MB, Smith
CR, Mack
M,
et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.
N Engl J Med. 2010;363(17):1597-1607. doi:
10.1056/NEJMoa1008232PubMedGoogle ScholarCrossref 6.Thyregod
HG, Steinbrüchel
DA, Ihlemann
N,
et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the All-Comers NOTION randomized clinical trial.
J Am Coll Cardiol. 2015;65(20):2184-2194. doi:
10.1016/j.jacc.2015.03.014PubMedGoogle ScholarCrossref 12.Linke
A, Wenaweser
P, Gerckens
U,
et al; ADVANCE study Investigators. Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study.
Eur Heart J. 2014;35(38):2672-2684. doi:
10.1093/eurheartj/ehu162PubMedGoogle ScholarCrossref 13.Bleiziffer
S, Bosmans
J, Brecker
S,
et al; ADVANCE Study Investigators. Insights on mid-term TAVR performance: 3-year clinical and echocardiographic results from the CoreValve ADVANCE study.
Clin Res Cardiol. 2017;106(10):784-795. doi:
10.1007/s00392-017-1120-3PubMedGoogle ScholarCrossref 14.Schymik
G, Lefèvre
T, Bartorelli
AL,
et al. European experience with the second-generation Edwards SAPIEN XT transcatheter heart valve in patients with severe aortic stenosis: 1-year outcomes from the SOURCE XT Registry.
JACC Cardiovasc Interv. 2015;8(5):657-669. doi:
10.1016/j.jcin.2014.10.026PubMedGoogle ScholarCrossref 18.Stortecky
S, Franzone
A, Heg
D,
et al. Temporal trends in adoption and outcomes of transcatheter aortic valve implantation: a SwissTAVI Registry analysis.
Eur Heart J Qual Care Clin Outcomes. 2019;5(3):242-251. doi:
10.1093/ehjqcco/qcy048PubMedGoogle ScholarCrossref 19.Chieffo
A, Petronio
AS, Mehilli
J,
et al; WIN-TAVI Investigators. 1-Year clinical outcomes in women after transcatheter aortic valve replacement: results from the first WIN-TAVI registry.
JACC Cardiovasc Interv. 2018;11(1):1-12. doi:
10.1016/j.jcin.2017.09.034PubMedGoogle ScholarCrossref 21.Wendler
O, Schymik
G, Treede
H,
et al. SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve.
Eur Heart J. 2017;38(36):2717-2726. doi:
10.1093/eurheartj/ehx294PubMedGoogle ScholarCrossref 27.Bosmans
J, Bleiziffer
S, Gerckens
U,
et al; ADVANCE Study Investigators. The incidence and predictors of early- and mid-term clinically relevant neurological events after transcatheter aortic valve replacement in real-world patients.
J Am Coll Cardiol. 2015;66(3):209-217. doi:
10.1016/j.jacc.2015.05.025PubMedGoogle ScholarCrossref 31.Lansky
AJ, Schofer
J, Tchetche
D,
et al. A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial.
Eur Heart J. 2015;36(31):2070-2078. doi:
10.1093/eurheartj/ehv191PubMedGoogle ScholarCrossref 33.Tay
EL, Gurvitch
R, Wijesinghe
N,
et al. A high-risk period for cerebrovascular events exists after transcatheter aortic valve implantation [correction published in
JACC Cardiovasc Interv. 2012;5(2):248].
JACC Cardiovasc Interv. 2011;4(12):1290-1297. doi:
10.1016/j.jcin.2011.08.012PubMedGoogle ScholarCrossref 35.Kleiman
NS, Maini
BJ, Reardon
MJ,
et al; CoreValve Investigators. Neurological events following transcatheter aortic valve replacement and their predictors: a report from the CoreValve trials.
Circ Cardiovasc Interv. 2016;9(9):e003551. doi:
10.1161/CIRCINTERVENTIONS.115.003551PubMedGoogle Scholar 36.Kapadia
S, Agarwal
S, Miller
DC,
et al. Insights into timing, risk factors, and outcomes of stroke and transient ischemic attack after transcatheter aortic valve replacement in the PARTNER trial (Placement of Aortic Transcatheter Valves).
Circ Cardiovasc Interv. 2016;9(9):e002981. doi:
10.1161/CIRCINTERVENTIONS.115.002981PubMedGoogle Scholar 37.Conrotto
F, D’Ascenzo
F, D’Onofrio
A,
et al. Predictive ability of the CHADS2 and CHA2DS2-VASc scores for stroke after transcatheter aortic balloon-expandable valve implantation: an Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER) sub-analysis.
Eur J Cardiothorac Surg. 2016;50(5):867-873. doi:
10.1093/ejcts/ezw199PubMedGoogle ScholarCrossref 38.Tarantini
G, Mojoli
M, Urena
M, Vahanian
A. Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome.
Eur Heart J. 2017;38(17):1285-1293.
PubMedGoogle Scholar 42.Piccolo
R, Pilgrim
T, Franzone
A,
et al. Frequency, timing, and impact of access-site and non-access-site bleeding on mortality among patients undergoing transcatheter aortic valve replacement.
JACC Cardiovasc Interv. 2017;10(14):1436-1446. doi:
10.1016/j.jcin.2017.04.034PubMedGoogle ScholarCrossref 45.Généreux
P, Cohen
DJ, Williams
MR,
et al. Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement: insights from the PARTNER I Trial (Placement of Aortic Transcatheter Valve).
J Am Coll Cardiol. 2014;63(11):1100-1109. doi:
10.1016/j.jacc.2013.10.058PubMedGoogle ScholarCrossref 48.Valgimigli
M, Bueno
H, Byrne
RA,
et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).
Eur Heart J. 2018;39(3):213-260. doi:
10.1093/eurheartj/ehx419PubMedGoogle ScholarCrossref 49.Levine
GN, Bates
ER, Bittl
JA,
et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
J Am Coll Cardiol. 2016;68(10):1082-1115. doi:
10.1016/j.jacc.2016.03.513PubMedGoogle ScholarCrossref 50.Lip
GYH, Collet
JP, de Caterina
R,
et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: executive summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
Thromb Haemost. 2017;117(12):2215-2236. doi:
10.1160/TH-17-10-0709PubMedGoogle ScholarCrossref 52.Lip
GYH, Collet
JP, Haude
M,
et al; ESC Scientific Document Group. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).
Europace. 2019;21(2):192-193. doi:
10.1093/europace/euy174PubMedGoogle ScholarCrossref 57.Rodés-Cabau
J, Masson
JB, Welsh
RC,
et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial.
JACC Cardiovasc Interv. 2017;10(13):1357-1365. doi:
10.1016/j.jcin.2017.04.014PubMedGoogle ScholarCrossref 58.D’Ascenzo
F, Benedetto
U, Bianco
M,
et al. Which is the best antiaggregant or anticoagulant therapy after TAVI? a propensity-matched analysis from the ITER registry: the management of DAPT after TAVI.
EuroIntervention. 2017;13(12):e1392-e1400. doi:
10.4244/EIJ-D-17-00198PubMedGoogle ScholarCrossref 62.Honda
Y, Yamawaki
M, Araki
M,
et al; OCEAN-TAVI investigators. Impact of HAS-BLED score to predict trans femoral transcatheter aortic valve replacement outcomes.
Catheter Cardiovasc Interv. 2018;92(7):1387-1396. doi:
10.1002/ccd.27596PubMedGoogle ScholarCrossref 63.Abdul-Jawad Altisent
O, Durand
E, Muñoz-García
AJ,
et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement.
JACC Cardiovasc Interv. 2016;9(16):1706-1717. doi:
10.1016/j.jcin.2016.06.025PubMedGoogle ScholarCrossref 65.Geis
NA, Kiriakou
C, Chorianopoulos
E, Uhlmann
L, Katus
HA, Bekeredjian
R. NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation.
Clin Res Cardiol. 2018;107(9):799-806. doi:
10.1007/s00392-018-1247-xPubMedGoogle ScholarCrossref 67.Vora
AN, Dai
D, Matsuoka
R,
et al. Incidence, management, and associated clinical outcomes of new-onset atrial fibrillation following transcatheter aortic valve replacement: an analysis from the STS/ACC TVT registry.
JACC Cardiovasc Interv. 2018;11(17):1746-1756. doi:
10.1016/j.jcin.2018.05.042PubMedGoogle ScholarCrossref